Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: four-year results of an open-label extension of 2 randomized clinical trials: TAP Report No. 7.
Bressler
Neil M
NM
Bressler
Susan B
SB
Haynes
Laurie A
LA
Hao
Yong
Y
Kaiser
Peter K
PK
Miller
Joan W
JW
Naor
Joel
J
Potter
Michael J
MJ
Pournaras
Constantin J
CJ
Reaves
Al
A
Rosenfeld
Philip J
PJ
Schmidt-Erfurth
Ursula
U
Slakter
Jason S
JS
Strong
Andrew
A
Vannier
Stéphane
S
D000368:Aged; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008268:Macular Degeneration / Q000150:complications / Q000188:drug therapy*; D008297:Male; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011166:Porphyrins / Q000627:therapeutic use*; D013997:Time Factors; D000077362:Verteporfin; D014792:Visual Acuity
D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin